## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Health Technology Appraisal**

Review proposal of NICE Technology Appraisal Guidance No. 69, on the use of Liquid Based Cytology (LBC) for the treatment of cervical cancer screening

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
CellPath Ltd (AutoCyte Prep)	Association of British Healthcare
Cytyc UK Ltd (ThinPrep)	Industries (ABHI)
Surgipath Europe Ltd (Cyto-screen)	Board of Community Health Councils in
TriPath Imaging Inc and Medical     Calutiana BLO (Coma Bath)	Wales
Solutions PLC (SurePath)	<ul><li>British National Formulary</li><li>Department of Health, Social Services</li></ul>
Patient/carer groups	Department of Health, Social Services and Public Safety for Northern Ireland
Cancer Voices	EUCOMED
Cancer voices     Cancerbackup	Medicines and Healthcare products
Gynae C	Regulatory Agency (MHRA)
Jo's Trust	National Public Health Service for
Macmillan Cancer Relief	Wales
Macriman Cancer Relief     Marie Curie Cancer Care	Newcastle Upon Tyne Hospitals NHS
National Cancer Alliance	Trust
National Council for Palliative Care	NHS Cancer Screening Programmes
Specialised Healthcare Alliance	NHS Confederation
Tenovus Cancer Information Centre	NHS Purchasing and Supply Agency
Women's Health Concern	NHS Quality Improvement Scotland
	Norfolk and Norwich University
Professional groups	Hospital NHS Trust
Association of Cancer Physicians	North Bristol NHS Trust
British Gynaecological Cancer	Patients Association
Society	Scottish Medicines Consortium
British Oncological Association	The UK National Screening Committee
British Psychosocial Oncology	(NSC)
Society	
British Society for Clinical Cytology	Comparator manufacturers
British Society of Colposcopy and	• (none)
Cervical Pathology	
Cancer Research UK	Relevant research groups
Community Practitioners' & Health	Institute of Cancer Research
Visitors Association	National Cancer Research Institute     National Trials Hait
Institute of Biomedical Science	MRC Clinical Trials Unit
Medical Women's Federation	The Eve Appeal

National Institute for Health and Clinical Excellence

Consultation on proposal for the review of NICE Technology Appraisal GuidanceNo. 69, on the use of Liquid Based Cytology (LBC) for the treatment of cervical cancer screening

Issue date: July 2007 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul> <li>National Association of Cytologists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Obstetrics and Gynaecology</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Society of Medicine – Intellectual Disabilities Forum</li> </ul>	<ul> <li>WellBeing of Women</li> <li>Assessment team</li> <li>School of Health &amp; Related Research, Sheffield (ScHARR)</li> <li>National Coordinating Centre for Health Technology Assessment</li> <li>Associated Guideline Groups</li> <li>National Collaborating Centre for Cancer</li> </ul>
<ul> <li>Others</li> <li>Department of Health</li> <li>Camden PCT</li> <li>Caerphilly LHB</li> <li>Welsh Assembly Government</li> </ul>	National Collaborating Centre for Women and Children's Health

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Issue date: July 2007 Page 2 of 3

#### **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations: the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

## Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

Issue date: July 2007 Page 3 of 3